Anti TNF alpha drugs for adults with moderate to severe non fistulizing active Chron's disease.
Vega-Coca MD, Araujo-Rodríguez F, Navarro-Palenzuela C, Márquez-Peláez S, Isabel-Gómez R, Beltrán-Calvo C, Molina-López T, Bautista-Paloma FJ, De Teresa-Galván FJ, Galindo-Galindo FJ, García-Sánchez V, López-Malo de Molina MD, Márquez-Galán JL, Monzón-Moreno A.
Record ID 32018000430
Spanish
Original Title:
Eficacia, seguridad y eficiencia de los fármacos anti-TNF alpha en el tratamiento de la enfermedad de Crohn no fistulizante, moderada-grave, en pacientes adultos
Authors' objectives:
To compare the efficacy, safety and efficiency of anti-TNF (infliximab and adalimumab) in the treatment of adult patients with moderate to severe non-fistulizing Crohn's disease.
Authors' results and conclusions:
Conclusions of efficacy and safety
-No studies directly comparing the efficacy and safety of infliximab and adalimumab in the treatment of adult patients with moderate to severe non-fistulizing Crohn's disease have been identified.
- Evidence from randomized placebo-controlled trials has shown that both infliximab and adalimumab are effective and safe options in the induction and maintenance treatment of adult patients with moderate to severe non-fistulizing Crohn's disease.
-The validity of indirect treatment comparisons is compromised by the heterogeneity between studies.
-In the absence of direct evidence to establish the superiority of one drug over another, both drugs can be considered as therapeutic alternatives with similar efficacy and safety.
Efficiency Conclusions
There was no empirical evidence that showed reliable conclusions about whether adalimumab or infliximab are clearly efficient in terms of cost-utility compared to conventional treatments. No firm conclusions could be drawn either in relation to the superiority of one treatment over the other.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
https://www.aetsa.org/publicacion/eficacia-seguridad-y-eficiencia-de-los-farmacos-anti-tnf-alpha-en-el-tratamiento-de-la-enfermedad-de-crohn-no-fistulizante-moderada-grave-en-pacientes-adultos/
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Spain
MeSH Terms
- Crohn Disease
- Tumor Necrosis Factor-alpha
- Antibodies
- Drug Therapy
- Infliximab
- Adalimumab
- Anti-Inflammatory Agents
- Adult
- Antirheumatic Agents
- Cost-Benefit Analysis
Contact
Organisation Name:
Andalusian Health Technology Assessment Area
Contact Address:
Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name:
aetsa.csalud@juntadeandalucia.es
Contact Email:
aetsa.csalud@juntadeandalucia.es
Copyright:
Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.